Immage Biotherapeutics Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IMMG research report →
About the company
Presently, Immage Biotherapeutics Corp. lacks substantial business operations. Historically, its endeavors centered on the creation of cutting-edge immunotherapy biologics designed to combat diverse cancer types across the United States.
- CEO
- Zhi Cong Mou
- IPO
- 2022
- Employees
- 3
- HQ
- Bethesda, US
Price Chart
- Market Cap
- $15.17K
- P/E
- -0.07
- P/S
- 0.00
- P/B
- 0.08
- EV/EBITDA
- 0.62
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -200.39%
- ROIC
- -90.18%
- Revenue
- $0 · 0.00%
- Net Income
- $-216,476 · -368269.47%
- EPS
- $-0.00 · -150.00%
- Op Income
- $-216,476
- FCF YoY
- -211688.55%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 32.51
- Avg Volume
- 700.8
Get TickerSpark's AI analysis on IMMG
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our IMMG coverage
Recent articles, reports, and earnings notes.
No research on IMMG yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IMMG report →Similar companies
Peers in the same neighborhood.